KR-20260062803-A - Antiviral or antibacterial Bio-patches and method of preparing the same

KR20260062803AKR 20260062803 AKR20260062803 AKR 20260062803AKR-20260062803-A

Abstract

The present invention relates to an antiviral or antimicrobial biopatch and a method for manufacturing the same. It provides an antimicrobial or antiviral biopatch comprising polydopamine, and a method for manufacturing a biopatch comprising the steps of preparing a polydopamine solution by mixing dopamine hydrochloride, deionized water, and Triss buffer, and forming a polydopamine layer on the skin.

Inventors

김봉훈
오준균
김장환
김호준
이수언
이한나
진호준

Assignees

재단법인대구경북과학기술원
단국대학교 산학협력단
아주대학교산학협력단

Dates

Publication Date: 20260507
Application Date: 20250616
Priority Date: 20241029

Claims (14)

Antimicrobial or antiviral biopatch containing polydopamine.
In paragraph 1, Antimicrobial or antiviral biopatch containing additional antibiotics.
In paragraph 2, The above antibiotic is, An antibacterial or antiviral biopatch comprising at least one selected from the group consisting of aminoglycoside antibiotics, β-lactam antibiotics, tetracycline antibiotics, macrolide antibiotics, glycopeptide antibiotics, quinolone antibiotics, and sulfonamide antibiotics.
In paragraph 3, The above-mentioned aminoglycoside antibiotic is, An antimicrobial or antiviral biopatch comprising at least one selected from the group consisting of tobramycin, gentamicin, streptomycin, kanamycin, neomycin, amikacin, spectinomycin, dibekacin, isokanamycin, ribostamycin, and paromycin.
In paragraph 1, The above antibacterial agent is, Antimicrobial or antiviral biopatch having antimicrobial activity against E. coli.
In paragraph 1, The above antiviral is, Antimicrobial or antiviral biopatch having antiadsorption activity against SARS-CoV-2 virus.
In paragraph 1, The above biopatch is, An antibacterial or antiviral biopatch characterized by having a thickness of 1 nm to 100 nm.
In paragraph 1, The above biopatch is, An antibacterial or antiviral biopatch characterized by acting as a skin barrier to maintain homeostasis on the surface of the epidermis.
In paragraph 1, The above biopatch is, Antimicrobial or antiviral biopatch that is a forming biopatch.
In Paragraph 9, The above-mentioned polydopamine is, An antibacterial or antiviral biopatch characterized by being polydopamine in liquid form.
In paragraph 1, The above biopatch is, An antibacterial or antiviral biopatch characterized by being formed to adhere closely to the skin's microtopography by mimicking the natural microstructure of the epidermis.
A composition for skin surface modification containing polydopamine.
In Paragraph 12, The above-mentioned skin surface modification composition is a skin surface modification composition having antibacterial or antiviral properties.
A step of preparing a polydopamine solution by mixing dopamine hydrochloride, deionized water, and Triss buffer, and A method for manufacturing a biopatch, comprising the step of forming a polydopamine layer on the skin.

Description

Antiviral or antibacterial bio-patches and method of preparing the same The present invention relates to an antiviral or antibacterial biopatch containing polydopamine and a method for manufacturing the same. The skin forms an effective barrier between the inside and outside of an organism and performs various protective functions. The epidermis protects the individual from physical threats such as mechanical injections and UV irradiation, regulates permeability, and prevents excessive moisture loss. Among the various barrier functions of the skin, its function as a biological immune barrier plays a crucial role as it is directly related to life; the skin barrier prevents the penetration of pathogens and can influence the attachment and proliferation of organic cells. The skin barrier, particularly the epidermis, can be easily damaged and its function impaired by various factors ranging from physical attacks such as scratches or abrasions to pathological conditions such as dermatitis and psoriasis. Exposure of internal tissues due to epidermal damage not only increases the risk of disease caused by external infectious agents such as bacteria, fungi, and viruses, but also triggers various health problems, including inflammatory responses and chronic skin diseases. The background description of the invention is provided to facilitate a better understanding of the present invention. The matters described in the background description should not be construed as an acknowledgment that they exist as prior art. FIG. 1a illustrates a schematic diagram showing the process of surface modification of human epidermis with an ultrathin mussel-derived polydopamine layer according to one embodiment of the present invention. FIG. 1b illustrates the results of human epidermal surface modification according to the polymerization time of a polydopamine layer according to one embodiment of the present invention. FIG. 1c illustrates the results of a Raman spectroscopic spectrum analysis of a polydopamine layer or a polydopamine layer combined with tobramycin (TOB) according to one embodiment of the present invention. FIG. 1d exemplarily illustrates the appearance of pores and body hair present on the human epidermis in a state of surface modification with an ultrathin polydopamine layer according to one embodiment of the present invention. FIG. 1e illustrates the results of optical microscopy observation of a pore surface-modified with a polydopamine layer according to one embodiment of the present invention. FIG. 1f shows the results of optical microscope and scanning electron microscope observations of body hair surface-modified with a polydopamine layer according to one embodiment of the present invention. FIG. 2a illustrates the results of optical microscopy observation over time of pig skin modified into a polydopamine layer using a static method according to one embodiment of the present invention. FIG. 2b illustrates the results of observing the transmission characteristics of RGB light through a polydopamine layer according to the modification time in one embodiment of the present invention. FIG. 2c illustrates the results of an analysis of surface energy changes of a polydopamine-treated epidermis based on the water contact angle according to one embodiment of the present invention. FIG. 2d illustrates the results of roughness analysis of a tomato surface and an orange surface treated with polydopamine according to one embodiment of the present invention. FIG. 2e illustrates the results of Raman spectroscopic spectrum analysis of a tomato surface and an orange surface treated with polydopamine according to one embodiment of the present invention. FIG. 2f illustrates the surface energy analysis results of a tomato surface, an orange surface, an apple surface, pig skin, and chicken skin based on whether the polydopamine layer surface is modified according to the water contact angle according to one embodiment of the present invention. FIG. 3a illustrates a schematic diagram showing a PDA layer according to one embodiment of the present invention acting as a barrier layer that maintains homeostasis on the surface of the epidermis. FIG. 3b illustrates a schematic diagram of a stacked wearable device stacked on a PDA layer according to one embodiment of the present invention. FIG. 3c illustrates an optical image of an impedance measuring device attached to a control group epidermis according to one embodiment of the present invention. FIG. 3d illustrates an optical image of an impedance measuring device attached to a PDA modified skin according to one embodiment of the present invention. FIG. 3e illustrates the results of an analysis of impedance changes according to frequency and time of a control group epidermis according to one embodiment of the present invention. FIG. 3f illustrates the results of an analysis of impedance changes according to frequency and time of a PDA-modified epidermis according to one embodiment of